Loading
companiesCompany
Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a United States-based biotechnology company running 3 late-stage cancer trials of CRN09682 in neuroendocrine tumours and pancreatic ductal adenocarcinoma.
Also called: Crinetics Pharmaceuticals Inc.
Overview
Crinetics Pharmaceuticals, based in San Diego, the United States, is a biotechnology company and part of Vertex Pharmaceuticals. Crinetics Pharmaceuticals is an endocrinology-focused pharmaceutical company that develops therapies for endocrine diseases and endocrine-related tumours. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing CRN09682 in neuroendocrine tumours and pancreatic ductal adenocarcinoma. The largest, NCT07129252 (A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumours), plans to enrol 150 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
San Diego, US
Scorecard
All companies#277of 1244 companies, score 16
- approved products +6
- targets +2
- modalities +2
- regions +1
- registry trials +5
1 approved, 0 in phase 3, 0 earlier, 1 targets, 7 registry studies. Formula on the scorecards page.
Type
Stage
Acquired
Website
ApprovedOral non-peptide somatostatin receptor 2 agonist
Paltusotine · Palsonify
Paltusotine is the first somatostatin-type drug that works as a once-daily pill instead of a monthly injection. It was approved in 2025 for acromegaly and is being tested for the flushing and diarrhoea of carcinoid syndrome from small-bowel neuroendocrine tumours.